Business
Hoth Therapeutics Provides Update for Novel COVID-19 Therapeutic, On-the-Go SARS-CoV-2 Testing Device, and Vaccine
Hoth Therapeutics expects key proof-of-concept data in Q4 2020 / Q1 2021 for its COVID-19 products it is currently developing NEW YORK, Nov. 2, 2020
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"Hoth Therapeutics expects key proof-of-concept data in Q4 2020 / Q1 2021 for its COVID-19 products it is currently developing\n\n\nNEW YORK, Nov. 2, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced key upcoming milestones towards the commercial development of the novel COVID-19 products currently being developed. Hoth Therapeutics has cast a wide net to contribute to the fight against COVID-19 that includes: HT-002 peptide therapeutic targeted to treat symptoms associated with COVID-19, the On-the-Go SARS-CoV-2 Testing Device, and VaxCelerate SARS-CoV-2 vaccine.\nHT-002HT-002 is a novel peptide therapeutic targeted for the treatment of illness associated with SARS-CoV-2 infection (COVID-19 disease).\nSARS-CoV-2 live virus inhibition test data is expected to be available in December 2020, which would characterize the therapeutic potential of the HT-002 peptide in an in vitro model. Pending results of the study, Hoth Therapeutics intends to pursue formulation development, preclinical safety testing, and meetings with the US Food and Drug Administration (\"FDA\") in 2021 for HT-002.\nOn-the-Go SARS-CoV-2 Testing DeviceThe On-the-Go SARS-CoV-2 Testing Device System is the first of its kind technology under development as a point-of-care/patient-use device as an aid in the diagnosis of COVID-19 infection. The system uses a nanohole array (NHA)-based plasmonic system that is being designed for high sensitivity and selectivity detection of SARS-CoV-2 virus with rapid reporting of results.\nThe On-the-Go SARS-CoV-2 Testing Device is currently in the research phase of development. Proof-of-concept data supporting sensitive detection of SARS-CoV-2 virus by prototype devices is expected by the end of 2020, with further studies characterizing specificity of the device contemplated in 2021. The initial research level data is expected to be used to support a pre-Emergency Use Authorization (EUA) meeting with the US Food and Drug Administration in 2021, which will be focused on the verification and validation requirements to obtain EUA for a non-laboratory use device.\n\"COVID-19 disease remains a critical unmet medical need in the US and there still exists a significant gap for effective vaccines, safe and efficacious therapeutics, and rapid, accurate diagnostic tests that can be perfor...